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Abstract
IMPORTANCE—Since licensure of the human papillomavirus (HPV) vaccine in 2006, HPV 
vaccine coverage among US adolescents has increased but remains low compared with other 
recommended vaccines.
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OBJECTIVE—To systematically review the literature on barriers to HPV vaccination among US 
adolescents to inform future efforts to increase HPV vaccine coverage.
EVIDENCE REVIEW—We searched PubMed and previous review articles to identify original 
research articles describing barriers to HPV vaccine initiation and completion among US 
adolescents. Only articles reporting data collected in 2009 or later were included. Findings from 
55 relevant articles were summarized by target populations: health care professionals, parents, 
underserved and disadvantaged populations, and males.
FINDINGS—Health care professionals cited financial concerns and parental attitudes and 
concerns as barriers to providing the HPV vaccine to patients. Parents often reported needing more 
information before vaccinating their children. Concerns about the vaccine’s effect on sexual 
behavior, low perceived risk of HPV infection, social influences, irregular preventive care, and 
vaccine cost were also identified as potential barriers among parents. Some parents of sons 
reported not vaccinating their sons because of the perceived lack of direct benefit. Parents 
consistently cited health care professional recommendations as one of the most important factors 
in their decision to vaccinate their children.
CONCLUSIONS AND RELEVANCE—Continued efforts are needed to ensure that health care 
professionals and parents understand the importance of vaccinating adolescents before they 
become sexually active. Health care professionals may benefit from guidance on communicating 
HPV recommendations to patients and parents. Further efforts are also needed to reduce missed 
opportunities for HPV vaccination when adolescents interface with the health care system. Efforts 
to increase uptake should take into account the specific needs of subgroups within the population. 
Efforts that address system-level barriers to vaccination may help to increase overall HPV vaccine 
uptake.
Human papillomavirus (HPV) infection is common, with prevalence peaking among young 
adults.1,2 Most HPV infections clear within 1 to 2 years, but persistent infections can 
progress to precancers or cancer. Nearly all cervical cancers and many vulvar, vaginal, 
penile, anal, and oropharyngeal cancers are caused by persistent infection with oncogenic or 
high-risk HPV types.3,4 HPV-16 and HPV-18 are responsible for 70% of cervical cancers 
and most noncervical HPV-associated cancers.5 A recent study6 found that more than 40% 
of females aged 14 to 59 years were HPV positive, and nearly 30% of infections were with 
high-risk types. Approximately 26 200 cancers per year are attributable to HPV (17 400 
among females and 8800 among males), many of which could be preventable with 
appropriate use of current or future vaccines.3
Two vaccines, a bivalent (HPV2) and a quadrivalent (HPV4) vaccine, are available to 
protect against HPV-16 and HPV-18.7 In addition, HPV4 protects against HPV-6 and 
HPV-11, which are responsible for 90% of genital warts.7 Both vaccines are administered as 
a 3-dose series. The Advisory Committee on Immunization Practices (ACIP) recommends 
routine vaccination of girls aged 11 to 12 years with either HPV2 or HPV4.8 The series can 
begin at age 9 years and is also recommended for females aged 13 to 26 years who have not 
initiated or completed the series. For boys aged 11 to 12 years, the ACIP recommends 
routine vaccination with HPV4.9 Vaccination with HPV4 for males can begin at age 9 years 
and is recommended for all males through age 21 years who have not initiated or completed 
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the series.HPV4 vaccination is also recommended for men who have sex with men or who 
are immunocompromised through age 26 years. Ideally, the vaccine should be administered 
before potential exposure to HPV through sexual contact.8,9
Healthy People 2020 objectives include increasing HPV vaccine series completion for 
females aged 13 to 15 years to 80% by the year 2020.10 Since vaccine licensure in 2006, 
HPV vaccine coverage among US females has increased but remains low compared with 
other recommended adolescent vaccines. Data from the 2011 National Immunization Survey 
(NIS)–Teen indicated that 53.0% of US girls aged 13 to 17 years had received at least 1 dose 
of the HPV vaccine and 34.8% had completed the 3-dose series.11 Healthy People 2020 
objectives do not address HPV vaccination among males, but vaccination of males is 
recommended to protect both males and their future sexual partners from HPV-related 
diseases.9 In 2011, 8.3% of US males aged 13 to 17 years had initiated the HPV vaccine 
series.11 This article systematically reviews the literature on barriers to HPV vaccination 
among US adolescents, both males and females, to inform future efforts to increase HPV 
vaccine coverage.
Methods
We searched PubMed using the following search string: human papillomavirus OR HPV OR 
human papillomavirus AND (vaccine OR vaccination OR vaccinate). We limited the search 
to original research articles published in English from January 1, 2009, through December 
31, 2012. One coauthor (D.M.H.) reviewed the titles and abstracts of all articles returned in 
the search and retrieved the full texts of potentially relevant articles to make a final 
determination of their relevance. The bibliographies of selected articles were scanned for 
additional relevant studies. Only articles that reported data collected in 2009 or later and 
addressed barriers to HPV vaccination among US adolescents aged 11 to 17 years were 
included. Articles that solely reported data collected before 2009 were excluded in an effort 
to focus on current barriers. Articles that focused on barriers to adult HPV vaccination or 
vaccination outside the United States were also excluded. One coauthor (D.M.H.) coded 
each article based on the target populations (eg, health care professionals, parents, and 
underserved populations) and topics (eg, completion and system-level barriers) addressed in 
the article. The coauthors (V.B., K.B.R., M.W., N.L., S.S.) then each abstracted and 
synthesized all findings related to a specific target population or topic. A second coauthor 
(D.M.H.) reviewed each section independently for accuracy. Disagreements were resolved 
by discussions among all the authors.
Results
The search in PubMed returned 2460 articles, of which 55 met the inclusion criteria. 
Findings are summarized in the Box and in the sections below by target populations: health 
care professionals, parents, underserved and disadvantaged populations, and males. The last 
section of the Results describes barriers to HPV vaccine series completion. Many articles 
reported quantitative data, but findings based solely on qualitative data are indicated as such 
within each section.
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Ten articles12–19,50,51 (18.2%) addressed barriers among health care professional to 
vaccinating their patients. Two studies17,19 identified continuing knowledge gaps. For 
example, some studies17,19 indicated low knowledge among health care professionals about 
the relationship between HPV infection and genital warts or the relationship between HPV 
and noncervical cancers. Two qualitative studies (N = 60 and 184 respondents) indicated 
that, when offering the vaccine to patients, health care professionals either offered little 
information about the vaccine, treating it like other recommended adolescent vaccines, or 
provided detailed information about the risks and benefits of the vaccine, highlighting it as 
optional.50,51 In 3 qualitative studies (N = 31–184 respondents), health care professionals 
reported using a risk-based approach according to the perceived level of the patient’s sexual 
activity or household characteristics51 and expressed a preference for vaccinating older vs 
younger adolescents50 and girls vs boys.17
Three other qualitative studies13,15,18 (N = 8–112 respondents) found that the most common 
barriers for health care professionals related to financial concerns. These concerns included 
cost to parents,13 cost to health care professionals,13 and inadequate insurance coverage and 
reimbursement.18 A study14 of Florida Medicaid providers (N = 428) found that those 
participating in the Vaccines For Children (VFC) program were less likely to cite cost of 
stocking the vaccine and lack of adequate or timely reimbursement as barriers compared 
with non-VFC providers.
Several qualitative studies12,16–18 (N = 21–112 respondents) found that health care 
professionals thought the decision to vaccinate was beyond their control and cited parental 
attitudes and concerns as a barrier. Concerns about safety and efficacy were rarely identified 
as barriers.16,18 One qualitative study16 (N = 34) found that some health care professionals 
did not view HPV as an important health threat, whereas others cited time constraints and 
forgetting to offer the vaccine as additional barriers.
Parents and Caregivers
Most studies11,13,20–43,50,51,53–59 (63.6%) addressed the barriers experienced by parents and 
caregivers. Studies indicated that most parents were aware of the vaccine,31,39,54 but parents 
reported needing more information before vaccinating their children and cited lack of 
knowledge as a barrier.* In one qualitative study (N = 32),29 parents reported that exposure 
to media and advertisement increased their knowledge and awareness of the vaccine. Some 
parents reported concerns about adverse effects, safety, and newness of the vaccine, but 
results were mixed as to whether such concerns hindered vaccine uptake.†
Across studies, few parents (1%–18%)expressed concern about the effect of vaccination on 
their child’s sexual behavior.13,20,26,35,38,40,42 In a qualitative study31 among African 
Americans (n = 19) and Haitian immigrants (n = 51), parents reported concern about 
vaccination being interpreted as condoning sexual activity but also appreciation for the 
protection that the vaccine could provide. In another qualitative study (N = 44),40 parents 
*References 13, 20–22, 24, 28, 31, 32, 34, 35, 40, 43
†References 13, 21, 25, 26, 28, 33–35, 40, 42, 53, 54
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reported concern about discussing the vaccine’s purpose with their children, which might 
necessitate discussion about sexual activity. In 2 other qualitative studies (N = 32–38),29,43 
parents indicated an interest in protecting their children before they became sexually active, 
and in many studies,21–24,29,34,50,55 perceived risk of HPV-related disease was a predictor of 
vaccine acceptance and series initiation.
Young age of the child was a common reason for refusing or delaying HPV vaccination,‡ 
and older girls were more likely to be vaccinated than younger girls.11,20,22,23,28,30,34,56 
Alternatively, in 2 studies (N = 403 and 700), age did not predict intention to vaccinate.54,58 
Vaccine acceptance was also associated with the belief that vaccinating one’s child was in 
accordance with social norms in 2 studies (N = 78 and 325).23,32 Furthermore, parents’ 
history of seeking preventive care for themselves or their children was positively associated 
with HPV vaccine uptake.26,28,34,56,58 Results were mixed as to whether parents’ previous 
HPV-related experiences (eg, prior abnormal Papanicolaou test, colposcopy, or cervical 
cancer) was correlated with acceptance of the HPV vaccine for one’s child. One quantitative 
study54 (N = 421) found that mothers with a history of HPV-related experiences were more 
likely to intend to vaccinate their daughters. Another study59 (N = 150) found similar results 
among non-Hispanic white and black mothers but not Hispanic mothers. Alternatively, 3 
other quantitative studies (N = 200–501) found no association between parents’ HPV-related 
experiences and HPV vaccine acceptance or uptake.25,26,33 Two studies (N = 70 and 400) 
indicated certain religious affiliations were associated with opposition to or nonreceipt of the 
HPV vaccine.31,57 However, in 2 other studies (N = 200 and 403), religiosity did not predict 
vaccine acceptance.25,54
Receiving a physician’s recommendation or discussing the HPV vaccine with a physician 
was associated with vaccine acceptance and initiation in numerous studies,§ and parents 
frequently cited not having a physician’s recommendation as the reason for not vaccinating 
their child.22,28,33,34,43 Furthermore, preventive care visits,22,56 increased contact with the 
medical system,37 and receipt of other recommended vaccines28,37 were associated with 
vaccine initiation in several studies. In contrast, only one study26 (N = 322) found that a 
physician’s consultation or recommendation did not influence vaccine uptake.
Findings were mixed regarding the cost of the HPV vaccine, with some identifying cost as a 
barrier13,26,33,35,38 and only one study (N = 403) indicating cost was not a barrier.54 A 
study20 among low-income, uninsured, ethnic minority, and immigrant women (N = 490) 
found that concerns about finding a clinic that offered the vaccine created additional 
barriers.
Underserved and Disadvantaged Populations
More than one-fourth (27.3%) of the studies ‖ addressed barriers among historically 
underserved populations (eg, minorities, those with a lower household income, and those 
without health insurance). Differences in HPV vaccine acceptance, initiation, and series 
‡References 22, 26, 28, 34, 35, 38, 40, 50, 51
§References 13, 21–25, 27, 29–31, 36, 38, 41
‖References 11, 13, 20, 22, 28, 31, 34, 39–41, 44, 52, 58–60
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completion have been noted across racial/ethnic groups.11,22,28,34,52 Recent data from NIS-
Teen indicate that black and Hispanic girls are less likely to complete the HPV vaccine 
series compared with whites11,22,52 and may be less likely to receive a recommendation for 
the vaccine from a health care professional.41
Most reported barriers to vaccination are similar across racial/ethnic groups but may affect 
some groups more than others. For example, one study44 (N = 309) that compared HPV 
vaccination among non-Hispanic white vs Hispanic girls found that the effects of age at first 
intercourse, mother-daughter communication about values related to sex, and social norms 
on vaccination status differed by ethnicity. In addition, a qualitative study40 among 
ethnically diverse black women (N = 44) found limited knowledge and confusion about 
HPV and the vaccine. Cultural differences can create unique barriers for specific 
subpopulations. For example, a qualitative study13 of 12 Hispanic immigrants identified 
immigration status, cultural factors, and distrust of health care facilities as barriers, and a 
study31 of 70 African American and Haitian immigrant mothers found distinct barriers 
between the 2 groups.
Studies11,52 also indicate a possible association between HPV vaccination and both 
household income and health insurance coverage. Data from NIS-Teen indicate that the 
highest rates of HPV vaccine initiation are among adolescents from households below the 
federal poverty level. Another study28 (N = 751) found that household income predicted 
vaccination initiation in boys only, with boys from homes with an annual household income 
of $50 000 or more being less likely to be vaccinated than those with a lower income. With 
regard to insurance status, data from NIS-Teen and one other study (N = 479)22,39 indicated 
that girls with public health insurance were more likely to initiate HPV vaccination 
compared with girls with private or no insurance coverage. In contrast, 2 studies found no 
association between vaccination (N = 700)58 or intent to vaccinate59 (N = 150) and 
insurance status.
One study60 (N = 50) described the unique barriers to vaccinating adolescents detained in 
juvenile justice facilities. Barriers included short length of stay, general lack of education 
regarding HPV vaccination, parental consent requirements, lack of adequate staff to 
administer the vaccine, staff reluctance to administer vaccine, lack of refrigerator storage 
space, patient fears, and cost.
Males
Eleven studies# (20.0%) examined barriers to male HPV vaccination. The NIS-Teen data 
indicate that uptake of the HPV vaccine is much lower among male adolescents than female 
adolescents.11 Similar to females, rates of vaccine series initiation are higher among black 
and Hispanic males compared with white males and higher among males below the poverty 
level compared with males living at or above the poverty level.11 Unlike females, HPV 
vaccine initiation does not vary with age among male adolescents,11 and one qualitative 
study40 among black women (N = 44) found mothers were more accepting of vaccinating 
sons at a young age than daughters. As mentioned previously, health care professionals may 
#References 11, 17, 26, 28, 35, 36, 40, 45, 46, 61, 62
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be more likely to recommend the vaccine to females than males.17,28 Furthermore, one 
qualitative study17 (N = 31) found that some health care professionals did not think 
vaccinating males was worth the cost or effort, were unaware of serious HPV-related disease 
in males, or thought that parents would not be interested in vaccinating their sons. Results 
from other studies indicated that parents were unclear about the need to vaccinate 
males,26,40 perceived the consequences of HPV infection as less severe for males,35 or were 
unaware that the vaccine could be given to males.35,61,62 One mixed-methods study46 
among adolescent males (N = 86) found that participants did not think they were sufficiently 
informed to make a decision about vaccination on their own. Parents and sons were more 
accepting of the vaccine if they perceived greater benefits for their sons or their sons’ future 
female partners,45,61,62 if their family or friends had positive views about the vaccine,46,62 
or if the vaccine was recommended by a physician.36,46 Cost was also cited as a potential 
barrier to vaccinating males in one study (N = 406).61
Vaccine Series Completion
Ten studies11,22,33,37,47–49,63–65 (18.2%) addressed barriers to completion of the 3-dose 
HPV vaccine series. Studies indicated that rates of HPV vaccine series completion tended to 
be lower among black11,22,33,37,47,48,64 and Hispanic22,33 girls and lower among those who 
lacked insurance coverage,48,64,66 a regular medical home,48 or a health care professional 
recommendation.33
One small study63 (N = 22) found some participants were unaware of or forgot the need for 
additional vaccine doses or were too busy for a return clinic visit. Another study37 (N = 
7702) found that increased contact with the medical system was associated with completion 
of the HPV vaccine series. Two retrospective cohort studies (N = 4117 and 271 976) found 
that younger adolescents were more likely to complete the series than older adolescents49,65 
and that completion rates varied by physician specialty, with higher rates of completion rates 
in pediatric departments49 and obstetrics-gynecology departments.65
Discussion
Since vaccine licensure, HPV vaccine coverage among US adolescents has increased but 
remains low compared with coverage for other vaccines recommended for adolescents (eg, 
70.5% coverage for meningococcal conjugate and 78.2% coverage for tetanus, diphtheria, 
and acellular pertussis in 2011).11 This systematic review summarizes the literature on 
barriers to HPV vaccination among this age group and will inform future efforts to increase 
vaccine uptake. The literature emphasizes the importance of receiving a recommendation for 
HPV vaccination from a health care professional. Most health care professionals offer the 
HPV vaccine and support adolescent HPV vaccination. However, health care professionals 
tend to be less likely to recommend the vaccine to younger patients and often recommend 
the vaccine based on perceived risk. Continued efforts are needed to ensure that health care 
professionals understand the importance of vaccinating adolescents before they become 
sexually active. Health care professionals may benefit from guidance on communicating 
HPV vaccine recommendations to patients and parents. In addition, although health care 
professionals may be finding ways to overcome financial challenges, the barriers related to 
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vaccine cost should not be ignored. Some have suggested expanding or increasing health 
care professional participation in the VFC programas potential strategies for reducing 
financial barriers.14,67
Parents are also critical to successful provision of the HPV vaccine. Parents want to protect 
their children from the harmful effects of HPV infection and are generally accepting of the 
vaccine. However, many report needing more information before vaccinating their children. 
Providing adequate, clear, and accessible information to parents about HPV infection, 
vaccine safety, adverse effects, and the appropriate age for vaccination may be one way 
health care professionals can reduce concerns and misconceptions about the vaccine. 
Communication efforts should also address logistical concerns (eg, vaccine financing).
Beliefs that only sexually active adolescents need the vaccine may lead parents to decline or 
delay HPV vaccination. Parents may underestimate their adolescents’ sexual experience and 
potentially miss an opportunity for prevention.68 Vaccinating at ages 11 or 12 years targets 
adolescents at an age when most are not yet sexually active and also when the immune 
response to vaccination is greater than it is at older ages.69
Communication efforts are also needed to highlight the benefits and importance of male 
vaccination. Studying the barriers to vaccinating high-risk male adolescents may pose 
challenges because of the sensitive nature of some of the risk factors for HPV infection in 
male adolescents.
Targeted efforts are also needed to increase vaccine uptake and completion among 
traditionally underserved populations. For example, HPV vaccine initiation is higher among 
blacks than whites, but rates of series completion are lower for blacks than whites.11 This 
disparity is concerning given that cervical cancer incidence and mortality are higher among 
black women than white women.70 Series completion is lower among females living below 
the poverty level compared with females living at or above poverty level.11 Information 
about the HPV vaccine should be distributed strategically to best reach underserved 
populations and provided in ways that are culturally sensitive, tailored to the target audience, 
and written at an appropriate reading level. School-based vaccination programs and health 
policy initiatives may further help to increase vaccine uptake and reduce disparities.48
The need for 3 doses of the HPV vaccine creates additional challenges for parents.71 
Adolescents generally encounter the health care system less frequently than any other age 
group72 and often seek only acute care or physical examinations for athletics.73 Providing 
opportunities for HPV vaccination in less traditional health care settings (eg, pharmacies and 
retail health clinics) and using reminder and recall systems may facilitate vaccine series 
completion.74 Innovative, communications-based interventions, including text message 
reminders and electronic medical records, may also increase series completion. However, 
such programs should take into account the specific populations they serve and consider that 
certain methods may not be effective for reaching underserved groups.63,75
Although studies typically identify barriers to HPV vaccination via reports from individual 
parents and health care professionals, many of the barriers identified stem from system- or 
organizational-level factors. For example, health care professionals consistently cite poor 
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insurance coverage or reimbursement and cost to purchase and store the vaccine as barriers. 
Among parents, vaccine cost and lack of insurance coverage are commonly noted. Most 
studies do not directly examine variation in HPV vaccination initiation or series completion 
at the system or organizational level. Several commentaries in the literature discuss the 
system-level barriers that likely influence overall uptake, including consent and 
confidentiality issues for adolescents,76–79 cultural stigma associated with a vaccine for a 
sexually transmitted disease,80,81 no usual source of care and decreased preventive services 
for adolescents,76–79 and confusing societal norms that are unclear about adolescent 
autonomy and responsibility for sex and health care decisions.77 All of these factors 
plausibly influence HPV vaccine uptake and should be considered when developing 
strategies to increase vaccine uptake and series completion. Multilevel analyses would be 
helpful for further understanding the role of system-level barriers on HPV vaccine uptake.
The literature search for this review yielded a large number of relevant studies, indicating 
that adolescent HPV vaccination is a high priority within public health and clinical 
communities. Despite the high volume of studies, study protocols and questionnaires varied 
widely. Use of standardized tools for collecting information about reasons for accepting or 
declining the HPV vaccine could facilitate more consistent data collection and enable 
researchers to more accurately compare barriers across groups and identify factors that 
facilitate HPV vaccination. One such tool is already available: the Carolina HPV 
Immunization Attitudes and Beliefs Scale provides standardized measures of parents’ 
attitudes and beliefs about the HPV vaccine.82 A similar tool is needed for collecting data on 
the barriers faced by health care professionals.
This review provides a systematic and comprehensive summary of the barriers to HPV 
vaccination that have been identified in the literature. A limitation of this review was that 
several commentaries that described system-level barriers were initially captured in the 
literature search but were ultimately excluded because they did not include analyses of 
original data. The system-level barriers described in those commentaries were examined 
briefly in the Discussion section.
In conclusion, this review describes the barriers to US adolescent HPV vaccination that have 
been identified in the literature. Barriers faced by health care professionals and parents 
should be carefully considered when developing strategies to improve HPV vaccine uptake 
and completion. Efforts should also address the needs of traditionally underserved groups, 
with particular sensitivity to social and cultural differences and the financial and logistical 
challenges that may have a greater effect on uptake among certain groups. Ultimately, 
efforts to better understand and address system-level barriers and social determinants of 
vaccination could potentially increase HPV vaccine uptake and completion among all US 
adolescents.83
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Summary of Key Barriers to HPV Vaccination Among US Adolescentsa
Health Care Professionals
Parents’ attitudes and concerns regarding HPV vaccination12,16–18
Financial concerns13,15,18
Knowledge gaps17,19
Inadequate insurance coverage and reimbursement14,18
Preference for vaccinating older vs younger adolescents50
Preference for vaccinating girls vs boys17
Parents
Not receiving a health care professional’s recommendation for the HPV vaccineb
Need more information about the HPV vaccinec
Belief that one’s child is too young to get vaccinated for HPVd
Concerns about vaccine adverse effects, safety, and newnesse
Cost of the HPV vaccinef
Concerns about finding a clinic that offers the HPV vaccine20
Underserved and Disadvantaged Populations
Limited knowledge about HPV and the HPV vaccine40,52
Lack of insurance coverage22,39
Not Receiving a Health Care Professional’s Recommendation for the HPV Vaccine41




Lack of perceived benefit or need to vaccinate males17,26,35,40
Lack of awareness that vaccine can be given to males35,44,45
Not receiving a health care professional’s recommendation for the HPV vaccine17,28
Cost of the vaccine44
Barriers Specific to Completion of the 3-Dose HPV Vaccine Series
Lack of insurance coverage47–49
Lack of a regular medical home47
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Lack of a health care professional recommendation33
Little contact with the medical system37
Being unaware of or forgetting about the need for additional doses46
Abbreviation: HPV, human papillomavirus.
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